Specialty Immunology Target hospitals and clinics focused on unmet immunology needs, leveraging Hemispherx's portfolio (Alferon N Injection and Ampligen) to position as a niche, high-value treatment option in external genital warts and immune-related conditions.

Clinical Trial Focus Identify opportunities to partner with research centers and contract research organizations for Ampligen and related therapies, highlighting ongoing or potential trials in oncology and immune disorders to expand study sites and patient access.

GMP Advantage Emphasize the U.S. GMP-certified manufacturing facility to attract potential CDMO and pharma partners for specialized production of high-purity biologics, enabling scale-up for clinical and early commercial demand.

Global Access Leverage Argentina approval for Naturaferon and potential international collaborations to explore regional distribution, regulatory pathways, and patient access programs in markets with unmet needs in chronic infections and immune-related diseases.

Early Access Programs Promote expansion of Early Access Programs to oncology and immunology indications, engaging patient advocacy groups and specialty networks to create trial-to-commercial pathways that could accelerate clinician adoption and payer engagement.